Estimating Price Trends For Seres Therapeutics Inc (NASDAQ: MCRB)

Seres Therapeutics Inc (NASDAQ:MCRB) does about 4.79M shares in volume on a normal day but saw 10149503 shares change hands in Monday trading. The company now has a market cap of 147.39M USD. Its current market price is $0.97, marking an increase of 19.85% compared to the previous close of $0.81. The 52 week high reached by this stock is $5.29 whilst the lowest price level in 52 weeks is $0.54.

Seres Therapeutics Inc (MCRB) has a 20-day trading average at $0.7450 and the current price is -81.60% off the 52-week high compared with 80.22% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.8814 and its 200-day simple moving average is $1.1239. If we look at the stock’s price movements over the week, volatility stands at 11.43%, which increases to 14.78% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 62.00 to suggest the stock is neutral.

The consensus objective for the share price is $3.31, suggesting that the stock has a potential upside of 70.69% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 26, 2023 when Oppenheimer resumed the stock to “Outperform” and issued a price target of $12. Goldman downgraded its price target at $24-$7.

Seres Therapeutics Inc (MCRB) stock is up 34.46% over the week and -14.63% over the past month. Its price is -30.49% year-to-date and -78.94% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of 0.36 below consensus estimates by -0.17. The company’s next earnings report forecasts estimating quarterly EPS at -0.27 and -1.04 for whole year.

To reach the target analysts have set, the stock logically needs to grow 70.69 percent from here.

The company has a return on investment of -56.78% and return on equity of -538.57%. The beta has a value of 1.96. Price to sales ratio is 1.16.